Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab add-on therapy for eosinophilic COPD with frequent exacerbations
NL-OMON54648Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Mepolizumab add-on with Placebo add-on (2 arms). Primary endpoint: Efficacy on moderate/severe COPD exacerbations. Started Jan 2020; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON54648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54648.